Monday, June 6, 2011

Impax receives FDA warning letter for Hayward plant

Generic drug maker Impax Laboratories Inc. received a warning letter from the FDA regarding sampling and testing of drugs at its Hayward plant.
Impax (NASDAQ: IPXL), which also has its headquarters and research and development in Hayward, said it was cited by the Food and Drug Administration for sampling and testing of materials and drug products, production record review and the company’s process for inspecting the failure of some manufacturing batches to meet specifications.

No comments:

Post a Comment